Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan/Natco, Sandoz/Momenta Stew As Teva Cements Copaxone Loyalty

This article was originally published in PharmAsia News

Executive Summary

Teva’s multiple sclerosis drug Copaxone lost patent protection about three weeks ago. But according to some analysts an immediate generic substitution is still up in the air and the company has not lost the opportunity to capitalize in the interim by switching patients to a new three-injections-a-week formulation.

You may also be interested in...



Teva Reorganizes With Emphasis On Strengthening Generics

Former Actavis Pharma President Olafsson has been appointed president and CEO of the newly formed Global Generic Medicines Group, which will consolidate Teva’s regional generic businesses under one group.

Teva’s Copaxone Suit Is “Absolutely Unprecedented,” FDA Says

FDA says Teva’s argument to court about dire impact of potential glatiramer ANDAs does not match its statements to investors.

Teva’s More Convenient Copaxone Puts Payors In A Bind

Teva Pharmaceutical’s recent launch of a more convenient formulation of its soon-to-be-generic multiple sclerosis blockbuster Copaxone puts payors in a quandary. They must choose whether to position it favorably on formularies, similar to the flexible standing that the original daily injection often enjoys, or restrict access to it in a way that has teeth.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC087377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel